Physician profile
Nutan Sharma
NPI 1700867975
$17,343.95
in general payments reported to CMS, 2019-2025
8 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,358 · 2020: $780 · 2023: $3,492 · 2024: $39.19 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $1,335 · Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,150.00 |
| Travel and Lodging | $1,335.20 |
| Food and Beverage | $720.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,672.05 | 2023-2025 | Botox |
| Allergan, INC. | $2,198.93 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $1,400.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $780.00 | 2020 | |
| Merz North America, INC. | $159.28 | 2019 | |
| Merz Pharmaceuticals, LLC | $94.50 | 2023 | Xeomin |
| Medtronic, INC. | $39.19 | 2024 | Percept PC Brainsense |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nutan Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.